Briacell Therapeutics CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
BriaCell Therapeutics Corp. announces its Annual General and Special Meeting for March 5, 2026, to address auditor appointment, director elections, and re-approval of its equity incentive plan.
NASDAQ
BriaCell Therapeutics Corp. has rescheduled its 2025 Annual General Meeting of Shareholders to February 5, 2025, due to postal service disruptions and to allow more time for proxy solicitation.
NASDAQ
BriaCell Therapeutics Corp. has scheduled its annual general meeting for January 23, 2025, to address key corporate matters including the appointment of auditors and the election of directors.